What are the effects and possible side effects of fenelinone?

Finerenone is a non-steroidal, selective mineralocorticoid receptor antagonist (MRA), mainly used for the treatment of patients with type 2 diabetes and chronic kidney disease (CKD). Its main effect is to delay the deterioration of kidney function, reduce proteinuria levels, and significantly reduce the risk of cardiovascular events. Compared with traditional MRA drugs such as spironolactone and eplerenone, fenelinone has higher selectivity and better safety, especially in terms of better control of the risk of hyperkalemia, and is therefore considered an important advance in the treatment of patients with CKD and type 2 diabetes.

Finelidone reduces inflammation and fibrotic responses by selectively inhibiting deleterious signaling pathways at mineralocorticoid receptors. Its therapeutic mechanism is not only limited to the classic effects of the anti-renin-angiotensin-aldosterone system (RAAS), but can also effectively reduce tubulointerstitial fibrosis and vascular endothelial damage. In multiple pivotal Phase III clinical trials, including FIDELIO-DKD and FIGARO-DKD, patients taking fenelidone had significantly better kidney disease progression than the placebo group, and the incidence of cardiovascular events was also reduced. These findings led to the regulatory approval of fenelidone in many countries and its inclusion in the recommended medications in international chronic kidney disease management guidelines.

Although fenelidone is generally well tolerated, there is still a certain risk of side effects during its use. The most important side effect is hyperkalemia, especially when patients are combined with RAAS inhibitors such as ACEI or ARB, blood potassium levels need to be closely monitored. Other adverse reactions include mild renal function decline, hypotension, dizziness, fatigue, etc., most of which are mild to moderate and reversible. In clinical practice, it is recommended to regularly monitor renal function and serum potassium during the initial stage of treatment and during dose adjustment to ensure medication safety.

Reference materials:https://www.kerendia.com/